The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer (mRCC).
J. L. Chen
No relevant relationships to disclose
D. E. Appelbaum
No relevant relationships to disclose
M. Kocherginsky
Research Funding - Novartis
K. Rathmell
Consultant or Advisory Role - AVEO; Novartis; Wyeth
Honoraria - Bayer; Onyx
Research Funding - Bayer; Onyx
D. F. McDermott
Consultant or Advisory Role - Biogen Idec; Bristol-Myers Squibb; Genentech; Prometheus; Roche
W. M. Stadler
Consultant or Advisory Role - Novartis